News
Net sales for the quarter and year ended December 31, 2022 were $10.1 million as we began to sell our sole commercial product, ROLVEDON, which was approved by the FDA on September 9, 2022.
Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ETCompany ParticipantsMichael Grabow - Executive Vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback